Financial Performance - The company's operating revenue for Q1 2023 was ¥34,739,572.68, a decrease of 46.40% compared to ¥64,818,635.90 in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥1,976,045.11, representing a decline of 1,335.77% from a profit of ¥159,904.25 in the previous year[5]. - Basic and diluted earnings per share were both -¥0.0063, a decrease of 1,360.00% from ¥0.0005 in the same period last year[5]. - Operating profit for the current period is -¥166,240.48, an improvement from -¥2,560,953.71 in the previous period[18]. - Net profit for the current period is ¥437,868.11, compared to a net loss of -¥3,237,533.29 in the previous period[18]. Cash Flow - The net cash flow from operating activities was ¥221,498.68, down 94.20% from ¥3,820,150.14 in the prior year[5]. - Cash flow from operating activities for the current period is ¥221,498.68, significantly lower than ¥3,820,150.14 in the previous period[20]. - Cash flow from investing activities shows a net outflow of -¥9,858,235.23, an improvement from -¥22,508,468.67 in the previous period[21]. - Cash flow from financing activities results in a net outflow of -¥3,440,558.04, compared to an inflow of ¥21,648,576.37 in the previous period[21]. - The ending cash and cash equivalents balance is ¥205,040,966.14, down from ¥155,964,954.55 in the previous period[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥554,426,832.54, an increase of 0.25% from ¥553,064,727.36 at the end of the previous year[5]. - The total liabilities increased slightly from 473,180,527.49 RMB to 474,104,764.56 RMB during the same period[15]. - The company's total equity as of March 31, 2023, was 80,322,067.98 RMB, up from 79,884,199.87 RMB at the beginning of the year[16]. - The cash and cash equivalents at the end of the reporting period were 205,070,966.14 RMB, compared to 218,148,260.73 RMB at the beginning of the year[13]. - The accounts receivable increased from 158,759,054.35 RMB to 168,247,960.76 RMB[13]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,088[10]. - The largest shareholder, Hunan Caixin Industrial Fund Management Co., Ltd., holds 25.58% of the shares, totaling 79,701,655 shares[10]. - The company has no preferred shareholders as of the reporting period[11]. Investment and Income - The company's investment income increased by 177.42% to ¥214,734.95 compared to a loss of ¥277,352.10 in the previous year[9]. - The company recorded a significant increase in non-operating income, totaling ¥1,000,000.00, up 761.12% from ¥116,127.27 in the previous year[9]. - The weighted average return on net assets was -15.46%, a decrease of 16.42% from 0.96% in the previous year[5]. - The company reported a 533.15% increase in trading financial assets, reaching ¥10,669,539.46, due to increased purchases of bank wealth management products[9]. Future Plans - The company plans to raise up to 276 million RMB through a private placement to supplement cash flow[12]. Audit Status - The first quarter report is not audited[22].

Financial Performance - The company's operating revenue for 2022 was ¥200,345,457.02, representing a 27.92% increase compared to ¥156,618,305.30 in 2021[22]. - The net profit attributable to shareholders of the listed company was -¥12,694,776.12, an improvement of 33.63% from -¥19,125,950.55 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥23,050,428.56, a decrease of 21.53% from -¥29,373,370.76 in 2021[22]. - Cash generated from operating activities increased by 55.35% to ¥166,381,243.04 from ¥107,098,005.73 in 2021[22]. - The total assets at the end of 2022 were CNY 553,064,727.36, a decrease of 16.11% from CNY 659,245,600.20 at the end of 2021[27]. - The net assets attributable to shareholders decreased by 17.24% to CNY 13,771,203.62 at the end of 2022 from CNY 16,640,394.08 at the end of 2021[27]. - The company reported a basic and diluted earnings per share of CNY -0.04 for 2022, improving from CNY -0.06 in 2021[27]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the past three years[27]. - The company reported a net profit of -¥29,761,420.25, indicating a significant discrepancy with the net cash flow from operating activities of ¥166,381,243.04, primarily due to growth in the cell storage business and improved collections from accounts receivable[81]. Business Strategy and Focus - The company has undergone a strategic adjustment in its major business focus from real estate and media to biomedicine and cell technology services since 2015[21]. - The company is focused on expanding its market presence in the biopharmaceutical sector, particularly in stem cell and immune cell storage services, leveraging its advanced technology and service quality[43]. - The company is actively involved in the development of new technologies in the biopharmaceutical field, including stem cell therapy and gene therapy, supported by national policies promoting innovation in healthcare[39]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[143]. - The company plans to strengthen its R&D capabilities by collaborating with research institutions and universities, focusing on stem cell and immune cell technologies[4]. Research and Development - The company has submitted nearly 30 intellectual property applications in the past three years, demonstrating a strong commitment to research and development in stem cell storage and clinical application technologies[44]. - The company has established a cell clinical application research system and built a cell flow culture room to enhance its capabilities in cell therapy and clinical transformation[44]. - R&D investment increased by 16.88% from ¥8,543,248.85 in 2021 to ¥9,985,226.68 in 2022, while the ratio of R&D investment to operating revenue decreased from 5.45% to 4.98%[74]. - The company is in the project initiation stage for a new hydrogel scaffold material for mesenchymal stem cell transplantation[71]. - The company aims to achieve clinical-grade autologous NK cell expansion, targeting the production of billions of NK cells from a single sample[72]. Market and Industry Trends - The energy-saving service industry in China has a total output value of 591.6 billion yuan, with a year-on-year growth of 13.3%, and is expected to reach 1 trillion yuan by 2025[37]. - The Chinese stem cell medical market was valued at 104.2 billion yuan in 2021, with projections indicating that the stem cell storage market will grow to 12.82 billion yuan by 2023, accounting for 9.41% of the total stem cell medical market[42]. - The company is positioned to benefit from the expanding market for cell therapy, which is expected to grow significantly in the coming years[35]. Governance and Management - The company maintains independent operations and governance, ensuring no interference from the controlling shareholder[117]. - The board of directors consists of 7 members, including 3 independent directors, adhering to governance regulations[118]. - The company has established a transparent information disclosure system, ensuring timely and accurate communication with investors[121]. - The company has a clear governance structure, with independent functioning of the shareholders' meeting, board of directors, and supervisory board[128]. - The company emphasizes the protection of stakeholder rights and maintains effective communication with investors[123]. Financial Management and Controls - The company has maintained effective internal controls over financial reporting as of December 31, 2022, with no significant deficiencies identified[177]. - The internal control self-assessment report indicated that all units included in the evaluation accounted for 100% of the company's total assets and revenue[175]. - The company reported a total audit fee of 61.35 million yuan for the fiscal year 2022, which includes 51.90 million yuan for financial audit services and 9.45 million yuan for internal control audit services[197]. - The company has not reported any significant changes in its financial performance or forecasts during the reporting period[192]. Employee and Talent Development - The total number of employees at the end of the reporting period was 512, with 287 in sales and 58 in production[166]. - The company plans to implement various training programs, including internal, external, and online training[169]. - The company has established a compensation policy that links income levels to company performance and departmental goals[170]. - The educational background of employees includes 7 with a doctorate, 33 with a master's degree, and 160 with a bachelor's degree[167]. Future Outlook - The company aims to enhance its operational efficiency and financial performance by optimizing its asset-liability structure and improving resource allocation[3]. - The company has set a performance guidance of 1.5 billion yuan in revenue for 2023, indicating a growth target of 25%[143]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficiency and user experience[147]. - The company plans to expand its market presence by entering three new provinces in 2023, aiming for a 15% increase in market share[143].

Financial Performance - The company's operating revenue for 2020 was ¥175,564,990.41, representing a 30.86% increase compared to ¥134,160,531.96 in 2019[18]. - The net profit attributable to shareholders of the listed company for 2020 was ¥8,154,550.92, a decrease of 56.64% from ¥18,806,368.87 in 2019[18]. - The overall net profit for the company was CNY 0.82 million, a decline of 56.64% year-on-year, primarily due to increased operational costs[43]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,654,615.66, an increase of 120.01% compared to the previous year[19]. - The net cash flow from operating activities was -¥207,220,871.68, a decrease of 1,526.91% year-on-year[19]. - The total assets at the end of 2020 were ¥556,140,141.52, representing a 107.26% increase from the end of 2019[19]. - The net assets attributable to shareholders increased by 44.28% to ¥26,568,530.39 compared to the end of 2019[19]. Business Operations - The company continues to focus on the biomedicine and cell technology services sector, which has been its main business since 2014[16]. - The revenue from the biopharmaceutical segment was ¥97,807,000, a decrease of 1.11% year-on-year, while the energy-saving and environmental protection segment revenue increased by 120.55% to ¥77,758,000[27]. - The company has established a clinical application research system for cell technology, enhancing its core competitiveness in cell storage services[30]. - The company received approval from the Hunan Provincial Health Commission to conduct stem cell and immune cell storage business in Hunan Province[31]. - The company has a professional technical team for stem cell and immune cell research, including Nobel Laureate Gregg L. Semenza, and has established strategic partnerships with renowned research institutions[32]. - The company has established a multi-level strategic cooperation mechanism with various hospitals for basic and clinical research, enhancing its market presence[35]. Shareholder and Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The actual controller of the company remains the Hunan Provincial People's Government after the share transfer[16]. - The company has maintained compliance with all commitments made to minority shareholders[110]. - The company guarantees that it will not engage in any business that competes with its main operations and will cease any such activities if they arise in the future[106]. - The company has not faced any delisting situations following the annual report disclosure[118]. - The company has established internal control mechanisms to prevent and detect material misstatements in financial reports[199]. Research and Development - The company initiated 6 independent R&D projects and 1 external research collaboration in 2020, focusing on stem cell and immune storage and detection[57]. - The number of R&D personnel increased by 50.00% from 92 in 2019 to 138 in 2020, accounting for 34.94% of the total workforce[63]. - R&D investment decreased by 67.93% from ¥15,515,677.43 in 2019 to ¥4,976,335.90 in 2020, representing only 2.83% of operating revenue[63]. Market and Industry Trends - The global stem cell market size was approximately $21.5 billion in 2010, exceeding $50 billion in 2014, and reaching $63.5 billion in 2015, with a compound annual growth rate of 24.2%[87]. - It is projected that the global stem cell market will reach $160 billion by 2021, indicating significant growth potential[87]. - In Hunan province, the stem cell storage rate is less than 1%, despite over 800,000 newborns annually, suggesting a vast market opportunity[87]. - The industry is experiencing increased competition, with foreign companies entering the market, posing challenges to domestic firms lacking core technologies and talent[94]. Financial Management - The company received financial support of ¥230 million from shareholders, contributing to a 46.99% increase in other payables[71]. - The company decided to extend a loan of 25.65 million yuan from Caixin Financial Holdings for one year at an interest rate of 4.35% per annum to supplement its liquidity[128]. - The company plans to borrow CNY 30 million from Hunan Caixin Financial Holdings Group for a period not exceeding 24 months at an interest rate of 4.75% per annum[130]. Audit and Compliance - The total audit fee for the current period was CNY 650,000, with CNY 550,000 allocated for the financial audit and internal control audit services[117]. - The internal control audit report was disclosed on March 31, 2021, and received a standard unqualified opinion[200]. - The company reported no significant internal control deficiencies during the reporting period[198]. Employee and Management Structure - The total number of employees is 395, with 384 from major subsidiaries and 11 from the parent company[176]. - The company adheres to a compensation policy linking income levels to company performance and long-term interests[178]. - The total remuneration for directors, supervisors, and senior management in the reporting period amounted to 2.8635 million yuan[173].

Financial Performance - The company's operating revenue for 2022 was ¥200,345,457.02, representing a 27.92% increase compared to ¥156,618,305.30 in 2021[21]. - The net profit attributable to shareholders was -¥12,694,776.12, an improvement of 33.63% from -¥19,125,950.55 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥23,050,428.56, a 21.53% improvement from -¥29,373,370.76 in 2021[21]. - Cash generated from operating activities increased by 55.35% to ¥166,381,243.04, up from ¥107,098,005.73 in 2021[21]. - The total assets at the end of 2022 were ¥553,064,727.36, a decrease of 16.11% from ¥659,245,600.20 at the end of 2021[26]. - The net assets attributable to shareholders decreased by 17.24% to ¥13,771,203.62 from ¥16,640,394.08 in 2021[26]. - The company reported a weighted average return on equity of -123.33% for 2022, compared to -112.47% in 2021[26]. - The company received government subsidies amounting to ¥6,829,849.35 in 2022, down from ¥8,630,913.98 in 2021[28]. - The total non-operating income and expenses for 2022 amounted to ¥10,355,652.44, slightly higher than ¥10,247,420.21 in 2021[29]. Business Strategy and Focus - The company has undergone a strategic adjustment in its major business focus from real estate and publishing to biomedicine and cell technology services since 2015[20]. - The company is actively involved in research and development in new products and technologies within the biomedicine sector[20]. - The company is positioned in a growing stem cell industry, with increasing government support for research and application in this field[33]. - The company aims to enhance the quality, reliability, and traceability of its products and services through information management and standard operating procedures[43]. - The company is focused on integrating existing R&D resources to create a tiered development framework in the biopharmaceutical field[103]. Revenue Breakdown - The company's total revenue for the reporting period was 200.35 million yuan, with the biopharmaceutical segment generating 142.70 million yuan, an increase of 18.15% year-on-year, and the energy-saving and environmental protection segment generating 57.48 million yuan, an increase of 60.35% year-on-year[42]. - The revenue from the energy-saving technology service sector was ¥57,480,136.60, accounting for 28.69% of total revenue, with a significant growth of 60.35% from ¥35,845,757.38 in 2021[58]. - The biopharmaceutical sector generated ¥142,696,749.00, which is 71.23% of total revenue, reflecting an 18.15% increase from ¥120,772,547.92 in the previous year[58]. - The revenue from cell storage and testing services was ¥135,930,334.24, which accounted for 67.85% of the total revenue from the biopharmaceutical sector[58]. Research and Development - The company has submitted nearly 30 intellectual property applications in the past three years, demonstrating its commitment to research and technology innovation in the field of stem cell storage and clinical applications[43]. - R&D investment increased by 16.88% to ¥9,985,226.68 in 2022, accounting for 4.98% of operating revenue[73]. - The company is in the project initiation phase for a new hydrogel scaffold material for mesenchymal stem cell transplantation, aiming to provide experimental data for clinical research[71]. - The company has completed the extraction and quality control process for mesenchymal stem cell exosomes, which may fill a gap in the field of stem cell exosome quality control[72]. Governance and Management - The company maintains independence from its controlling shareholder, ensuring no interference in decision-making or operations, and no fund occupation by the controlling shareholder[116]. - The board of directors consists of 7 members, including 3 independent directors, adhering to governance regulations[117]. - The company has established a transparent information disclosure system, ensuring timely and accurate communication with investors[120]. - The company has committed to compliance and governance, with independent directors and a dedicated audit team ensuring transparency and accountability[138][140]. Market Expansion and Future Plans - In 2023, the company aims to optimize its asset-liability structure and enhance its financial resilience by issuing shares to specific investors, which is currently in progress[102]. - The company plans to strengthen its R&D capabilities by collaborating with research institutions and universities, focusing on stem cell and immune cell technologies[103]. - Market expansion plans include entering two new provinces, targeting an additional 500,000 users[147]. - The company has completed a strategic acquisition of a local biotech firm for 100 million yuan to enhance its product portfolio[147]. Employee and Talent Management - The total number of employees at the end of the reporting period was 512, with 287 in sales and 58 in production[164]. - The educational background of employees includes 7 with a doctorate, 33 with a master's degree, and 160 with a bachelor's degree[165]. - The company has implemented a training program that includes internal, external, and online training methods[166]. - The company emphasizes the importance of talent development and plans to build a robust talent cultivation system to support its strategic goals[105]. Legal and Compliance - The company faced a lawsuit regarding a technical authorization agreement, with a claimed amount of CNY 737.99 million, but it has not formed a provision for this liability[197]. - The company has not faced any penalties or rectifications during the reporting period[200]. - The company has not engaged in any illegal occupation of assets or funds during the reporting period[189]. Financial Management - The company reported a significant increase in cash flow from its cell storage business, contributing positively to cash flow despite overall net losses[80]. - The company has committed to avoiding any form of competition with its controlling shareholders and related enterprises[186]. - The company guarantees that all related transactions will be conducted at market prices and in compliance with relevant regulations[187].

南华生物医药股份有限公司2021年年度报告全文 南华生物医药股份有限公司 2021 年年度报告 ...

Key Financial Data [Key Accounting Data and Financial Indicators](index=2&type=section&id=%28I%29%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company achieved significant revenue growth and turned profitable in the first three quarters of 2022, with net profit attributable to parent company shareholders up 106.44%, despite a decline in total assets Key Accounting Data and Financial Indicators | Indicator | Year-to-Date as of Report Period End | YTD vs. Prior Period Change | | :--- | :--- | :--- | | Operating Revenue (CNY) | 156,404,576.30 | 52.40% | | Net Profit Attributable to Shareholders of the Listed Company (CNY) | 540,721.32 | 106.44% | | Net Profit Attributable to Shareholders of the Listed Company After Deducting Non-recurring Gains and Losses (CNY) | -6,212,530.03 | 46.46% | | Net Cash Flow from Operating Activities (CNY) | 130,252,235.42 | 364.07% | | Basic Earnings Per Share (CNY/share) | 0.0017 | 106.30% | | **Indicator** | **As of End of Current Period** | **Vs. Prior Year-End Change** | | Total Assets (CNY) | 596,009,995.11 | -9.59% | | Total Equity Attributable to Shareholders of the Listed Company (CNY) | 17,181,115.40 | 3.25% | [Non-recurring Gains and Losses and Their Amounts](index=2&type=section&id=%28II%29%20Non-recurring%20Gains%20and%20Losses%20and%20Their%20Amounts) Year-to-date, non-recurring gains and losses totaled **6.75 million CNY**, primarily from government grants, which was key to achieving positive net profit Non-recurring Gains and Losses | Item | YTD Amount (CNY) | Description | | :--- | :--- | :--- | | Government grants recognized in current profit or loss | 3,565,005.85 | - | | Other non-operating income and expenses apart from the above | 4,619,397.82 | - | | Impact on minority interests (after tax) | -1,282,115.66 | - | | **Total** | **6,753,251.35** | **--** | [Changes and Reasons for Key Financial Indicators](index=3&type=section&id=%28III%29%20Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Significant financial changes include increased financial assets held for trading, decreased prepayments, increased short-term borrowings, and reduced other payables; revenue grew over 50%, with credit impairment losses reversing Key Financial Indicator Changes and Reasons | Statement Item | Change Percentage | Reason for Change | | :--- | :--- | :--- | | **Balance Sheet** | | | | Financial assets held for trading | 2014.90% | Primarily due to debt-to-equity conversion by a subsidiary and current period purchases of wealth management products | | Prepayments | -70.90% | Due to recovery of business prepayments from canceled procurement agreements in the current period | | Short-term borrowings | 91.33% | Increase in bank borrowings | | Other payables | -35.93% | Primarily due to repayment of 100 million CNY loan from Caixin Financial Holdings in the current period | | **Income Statement** | | | | Operating revenue | 52.40% | Continued growth in the company's cell business and new heating business revenue compared to the prior period | | Operating cost | 282.60% | Increase in operating revenue led to a corresponding increase in costs | | Other income | 394.03% | Increase in government grants received in the current period | | Credit impairment losses | 150.01% | Recovery of accounts receivable from energy-saving and medical device trading businesses in the current period, leading to a reversal of corresponding bad debts | Shareholder Information [Common Shareholder Shareholding](index=4&type=section&id=%28I%29%20Total%20Number%20of%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Shareholding) As of the report period end, the company had **13,960** common shareholders; the controlling shareholder holds **25.58%**, with some top shareholders having pledged shares - As of the report period end, the total number of common shareholders was **13,960**[13](index=13&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shareholder Type | Shareholding Percentage | Number of Shares Held | Pledge Status | | :--- | :--- | :--- | :--- | :--- | | Hunan Caixin Industrial Fund Management Co., Ltd. | State-owned Legal Person | 25.58% | 79,701,655 | None | | Shanghai Heping Bulk Equity Investment Fund Management Co., Ltd. | Domestic Non-state-owned Legal Person | 11.43% | 35,600,000 | Pledged 35,600,000 | | Hefei Xijing Technology Co., Ltd. | Domestic Non-state-owned Legal Person | 4.66% | 14,522,162 | None | - The company's controlling shareholder, Caixin Industrial Fund, has no related party or concerted action relationship with other shareholders; relationships among other circulating shareholders are unknown[14](index=14&type=chunk) Other Significant Matters [Other Significant Matters](index=6&type=section&id=III.%20Other%20Significant%20Matters) No other significant matters required disclosure during the reporting period - The company had no other significant matters requiring disclosure in this reporting period[16](index=16&type=chunk) Quarterly Financial Statements (Unaudited) [Consolidated Balance Sheet](index=6&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of September 30, 2022, total assets were **596.01 million CNY**, down 9.59%; total liabilities were **477.53 million CNY**, down 13.01% due to debt repayment; equity attributable to parent company shareholders was **17.18 million CNY**, a slight increase Consolidated Balance Sheet Data | Item | September 30, 2022 (CNY) | January 1, 2022 (CNY) | | :--- | :--- | :--- | | Total Assets | 596,009,995.11 | 659,245,600.20 | | Total Liabilities | 477,530,805.14 | 548,926,321.40 | | Total Equity Attributable to Parent Company Shareholders | 17,181,115.40 | 16,640,394.08 | | Total Equity | 118,479,189.97 | 110,319,278.80 | [Consolidated Income Statement](index=8&type=section&id=2.%20Consolidated%20Income%20Statement%20from%20Year-Beginning%20to%20Report%20Period%20End) In the first three quarters of 2022, operating revenue reached **156.40 million CNY**, up 52.40%, with total operating costs at **152.42 million CNY**, up 40.70%; net profit was **8.16 million CNY**, a turnaround from a **5.36 million CNY** net loss, with parent company net profit at **0.54 million CNY** Consolidated Income Statement Data | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | I. Total Operating Revenue | 156,404,576.30 | 102,630,862.82 | | II. Total Operating Costs | 152,421,445.83 | 108,336,750.17 | | III. Operating Profit | 8,389,117.25 | -6,144,236.87 | | IV. Total Profit | 13,007,165.63 | -3,236,487.92 | | V. Net Profit | 8,159,911.17 | -5,357,485.10 | | 1. Net Profit Attributable to Parent Company Shareholders | 540,721.32 | -8,401,491.52 | | 2. Minority Interests | 7,619,189.85 | 3,044,006.42 | [Consolidated Cash Flow Statement](index=10&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement%20from%20Year-Beginning%20to%20Report%20Period%20End) In the first three quarters of 2022, operating cash flow was a strong net inflow of **130.25 million CNY**, up 364.07%; investing cash flow was a net outflow of **20.89 million CNY**, while financing cash flow was a net outflow of **73.54 million CNY** due to debt repayment; cash and cash equivalents at period end totaled **188.83 million CNY** Consolidated Cash Flow Statement Data | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 130,252,235.42 | 28,067,646.06 | | Net Cash Flow from Investing Activities | -20,892,052.90 | -20,418,020.02 | | Net Cash Flow from Financing Activities | -73,539,523.05 | 24,749,939.87 | | Net Increase in Cash and Cash Equivalents | 35,820,788.38 | 32,399,541.03 | | Cash and Cash Equivalents at Period End | 188,825,485.09 | 99,437,580.79 | [Audit Status](index=11&type=section&id=%28II%29%20Audit%20Report) The company's 2022 third-quarter report is unaudited - The company's third-quarter report is unaudited[24](index=24&type=chunk)

Financial Performance - The company's operating revenue for the first half of 2022 was ¥109,777,202.11, representing a 62.87% increase compared to ¥67,401,236.63 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥2,166,923.99, a significant turnaround from a loss of ¥6,298,477.35 in the previous year, marking a 134.40% improvement[19]. - The net cash flow from operating activities reached ¥111,323,801.11, a remarkable increase of 1,533.93% compared to a negative cash flow of ¥7,763,557.85 in the same period last year[19]. - Basic and diluted earnings per share improved to ¥0.0070, up 134.65% from a loss of ¥0.0202 per share in the previous year[19]. - The weighted average return on net assets was 12.23%, a recovery of 39.12% from -26.89% in the same period last year[19]. - The operating cost increased significantly by 338.53% to ¥49,672,972.00, up from ¥11,327,132.48, primarily due to the increase in operating revenue[53]. - The company reported a significant increase in other income, which rose by 290.13% to ¥2,277,057.77, mainly due to government subsidies received[53]. - The total profit for the first half of 2022 was CNY 6,384,666.19, a significant improvement from a total loss of CNY 3,880,301.46 in the previous year[164]. Assets and Liabilities - Total assets decreased by 14.71% to ¥562,260,133.11 from ¥659,245,600.20 at the end of the previous year[19]. - The net assets attributable to shareholders increased by 13.02% to ¥18,807,318.07 from ¥16,640,394.08 at the end of the previous year[19]. - The company's cash and cash equivalents decreased by 54.81% to ¥7,046,281.82 from ¥15,593,355.93, primarily due to cash outflows from investment and financing activities[53]. - Accounts receivable amounted to ¥194,983,489, accounting for 34.68% of total assets, an increase of 4.93% from the previous year[63]. - Total liabilities decreased to CNY 448,064,145.00 from CNY 548,926,321.40, indicating a reduction of approximately 18.4%[157]. - Current liabilities totaled CNY 430,191,289.89, down from CNY 529,002,426.65, a decrease of about 18.7%[157]. Market and Industry Trends - The global stem cell industry is entering a rapid growth phase, with China's market share increasing from 18.8% in 2016 to 21.9% in 2020[30]. - The cell therapy market in China is expected to grow from 1.3 billion yuan in 2021 to 10.2 billion yuan by 2023, with a compound annual growth rate of 181.5%[31]. - The environmental protection industry in China is projected to maintain a growth rate of 15-20% during the 14th Five-Year Plan period[32]. - The company operates in two main sectors: "biomedicine" and "energy conservation and environmental protection"[28]. Research and Development - The company is actively involved in stem cell storage and application research, supported by various national policies[29]. - The number of new stem cell drug application projects in the first half of 2022 reached 8, indicating a growing interest in the field[31]. - The company is focused on upstream cell storage technology services while simultaneously conducting technology research and development[36]. - The company is actively engaged in the research and development of new medical technologies and products, which is crucial for future growth[77]. Strategic Initiatives - The company plans to expand its market presence in energy-saving products and services, particularly in urban heating operations, which is expected to drive future revenue growth[60]. - The company plans to enhance brand awareness and improve employee expertise to increase the conversion rate of newborn stem cell storage[85]. - The company intends to increase investment in technology research and development, leveraging national and local support policies for the stem cell industry to create new growth points[85]. - The company plans to enhance governance, internal control systems, and talent development to address bottlenecks in rapid growth[92]. Risks and Challenges - The company faces risks related to changes in tax incentives for energy-saving projects, which could adversely affect profitability if it no longer qualifies for such benefits[86]. - The company is exposed to funding recovery risks due to the long project cycles in the energy-saving sector, which may strain liquidity and increase operational risks[87]. - The company reported a significant decline in potential customer base due to a decreasing birth rate, with national birth rates recorded at 10.41‰, 8.52‰, and 7.52‰ from 2019 to 2021, respectively[81]. Shareholder Information - The company plans to issue up to 18,449,197 A-shares to its controlling shareholder, raising no more than RMB 276 million to supplement working capital[134]. - The total number of ordinary shareholders at the end of the reporting period is 14,059[141]. - Hunan Caixin Industrial Fund holds 25.58% of the shares, totaling 79,701,650 shares[141]. - The company has not reported any share buyback progress[139]. Compliance and Governance - The half-year financial report has not been audited[110]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[108].

Financial Performance - The company's operating revenue for 2021 was ¥156,618,305.30, a decrease of 10.79% compared to ¥175,564,990.41 in 2020[19] - The net profit attributable to shareholders of the listed company was -¥19,125,950.55 in 2021, representing a decline of 334.54% from a profit of ¥8,154,550.92 in 2020[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -29,373,370.76 CNY, a decrease of 619.46% compared to the previous year[20] - The operating cash flow was 107,098,005.73 CNY, an increase of 151.68% compared to the previous year[20] - The total assets at the end of 2021 were 659,245,600.20 CNY, representing an 18.54% increase from the end of 2020[20] - The net assets attributable to shareholders decreased by 37.37% to 16,640,394.08 CNY compared to the end of 2020[20] - The revenue from main business after deductions was 137,487,362.78 CNY, compared to 175,432,248.87 CNY in 2020[21] - The company reported a quarterly operating revenue of 53,987,442.48 CNY in Q4 2021, showing a positive trend in the latter part of the year[25] - The company received government subsidies amounting to 8,630,913.98 CNY, which are closely related to its normal business operations[26] Business Strategy and Focus - The company has shifted its main business focus to biomedicine and cell technology services since 2015, moving away from its previous real estate and publishing operations[18] - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[6] - The company is positioned in a rapidly growing industry, with significant government support for biomedicine and cell therapy technologies[31] - The company is committed to enhancing its competitive advantage in the biopharmaceutical industry through innovation and collaboration in research and development[37] - The company plans to focus on core technologies and deepen its main business, particularly in stem cell and immune cell technology applications[97] - The company aims to enhance resource allocation and adjust its operational and marketing strategies in 2022[97] Research and Development - The company has completed over 50 national-level research projects, including the "973 Program" and "863 Program," resulting in 200+ high-level SCI research papers and 17 national invention patents[42] - The company is actively involved in research projects, including the use of umbilical cord mesenchymal stem cells for treating pediatric biliary atresia and neural stem cell therapy for Alzheimer's disease[37] - The company initiated multiple R&D projects, including a new culture system for umbilical cord mesenchymal stem cells, with expected completion by December 2022[66] - R&D investment increased by 71.68% from 4,976,335.90 yuan in 2020 to 8,543,248.85 yuan in 2021, with R&D investment as a percentage of operating revenue rising from 2.83% to 5.45%[71] Market Position and Growth - The cell therapy market in China is expected to grow from 1.3 billion CNY in 2021 to 10.2 billion CNY by 2023, with a compound annual growth rate of 181.5%[32] - The company achieved a total revenue of CNY 156.62 million in 2021, with the biopharmaceutical segment generating CNY 120.77 million, representing a year-on-year growth of 23.48%[38] - The environmental protection segment reported revenue of CNY 35.85 million, showing a significant decline of 53.90% compared to the previous year[38] - The company reported a total revenue of 259.97 million in 2021, with a net loss of 12.18 million[93] Governance and Management - The actual controller of the company is the Hunan Provincial Government, with the largest shareholder being the Hunan Caixin Industrial Fund Management Co., Ltd., a state-owned enterprise[39] - The company has established a transparent information disclosure system, ensuring timely and accurate communication with investors through various channels[114] - The company has held 1 annual general meeting and 3 extraordinary general meetings during the reporting period, ensuring compliance with legal requirements for shareholder meetings[109] - The board of directors has undergone changes, with new appointments aimed at strengthening governance and strategic direction[127] - The company has appointed independent directors with extensive experience in finance and law, strengthening its oversight capabilities[135][136] Financial Management and Expenses - Sales expenses increased by 53.35% to ¥57,682,332.01 due to higher revenue from cell business and the establishment of new subsidiaries[65] - Management expenses rose by 57.95% to ¥48,234,324.81, driven by increased personnel and relocation costs[65] - Financial expenses surged by 324.81% to ¥13,988,841.62, primarily due to the continued use of a significant loan from a major shareholder[65] - The total remuneration for directors, supervisors, and senior management in the reporting period amounted to CNY 3.0992 million[146] Employee and Talent Development - The total number of employees at the end of the reporting period was 539, with 11 in the parent company and 528 in major subsidiaries[159] - The professional composition included 309 sales personnel, 55 production personnel, 31 technical personnel, 23 financial personnel, and 121 administrative personnel[160] - The company has a training plan that includes internal training, external training, and online training to enhance employee skills[161] - The company emphasizes the importance of talent development, planning to stabilize the current R&D team while attracting top technical personnel to enhance research capabilities[102] Compliance and Risk Management - The internal control system has been effectively established and executed, with no significant deficiencies reported[165] - The company maintained effective internal control over financial reporting as of December 31, 2021[171] - The audit committee held 2 meetings during the reporting period, discussing the annual report and financial statements[156] - The company did not identify any risks during the supervisory activities of the supervisory board in the reporting period[158] Environmental and Social Responsibility - The company faced an administrative penalty due to a wastewater detection equipment failure, resulting in a fine of 20,000 yuan[176] - There were no significant environmental issues reported during the period, and the company is not classified as a key pollutant discharge unit[176] - The company has not reported any activities related to poverty alleviation or rural revitalization[179]

南华生物医药股份有限公司 2022 年第一季度报告全文 证券代码：000504 证券简称：南华生物 公告编号：2022-044 南华生物医药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 64,818,635.90 | 33,131,542.07 | 95.64% | | 归属于上市公司股东的净利润（元） | 159,904.25 | ...

南华生物医药股份有限公司 2021 年第三季度报告 证券代码：000504 证券简称：南华生物 公告编号：2021-050 南华生物医药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信 息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 1 南华生物医药股份有限公司 2021 年第三季度报告 | 归属于上市公司股东的 | 18,167,038.87 | 26,568,530.39 | -31.62% | | --- | --- | --- | --- | | 所有者权益（元） | | | | (二)非经常性损益项目和金额 √ 适用 □ 不适用 单位 ...